{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:07:23Z","timestamp":1789679243962,"version":"4.0.1"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40262-025-01492-6","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T18:37:06Z","timestamp":1741199826000},"page":"511-531","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5321-0816","authenticated-orcid":false,"given":"M. P.","family":"Kicken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"Deenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"van der Wekken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. E. E. M.","family":"van den Borne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"issue":"3","key":"1492_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"1492_CR2","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1038\/modpathol.2011.150","volume":"25","author":"WD Travis","year":"2012","unstructured":"Travis WD. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol. 2012;25(Suppl 1):S18-30.","journal-title":"Mod Pathol"},{"issue":"12","key":"1492_CR3","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","volume":"32","author":"J Remon","year":"2021","unstructured":"Remon J, Soria JC, Peters S. Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy. Ann Oncol. 2021;32(12):1637\u201342.","journal-title":"Ann Oncol"},{"issue":"4","key":"1492_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(4):358\u201376.","journal-title":"Ann Oncol"},{"key":"1492_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jconrel.2022.10.043","volume":"352","author":"L DeRidder","year":"2022","unstructured":"DeRidder L, Rubinson DA, Langer R, Traverso G. The past, present, and future of chemotherapy with a focus on individualization of drug dosing. J Control Release. 2022;352:840\u201360.","journal-title":"J Control Release"},{"key":"1492_CR6","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"13","key":"1492_CR7","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0959-8049(02)00151-X","volume":"38","author":"A Felici","year":"2002","unstructured":"Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002;38(13):1677\u201384.","journal-title":"Eur J Cancer"},{"issue":"6","key":"1492_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/cts.12490","volume":"10","author":"D Gonzalez","year":"2017","unstructured":"Gonzalez D, Rao GG, Bailey SC, Brouwer KLR, Cao Y, Crona DJ, et al. Precision dosing: public health need, proposed framework, and anticipated impact. Clin Transl Sci. 2017;10(6):443\u201354.","journal-title":"Clin Transl Sci"},{"key":"1492_CR9","doi-asserted-by":"publisher","first-page":"1144056","DOI":"10.3389\/fonc.2023.1144056","volume":"13","author":"R Murphy","year":"2023","unstructured":"Murphy R, Halford S, Symeonides SN. Project Optimus, an FDA initiative: considerations for cancer drug development internationally, from an academic perspective. Front Oncol. 2023;13:1144056.","journal-title":"Front Oncol"},{"issue":"3","key":"1492_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41571-023-00853-z","volume":"21","author":"S Rodney","year":"2024","unstructured":"Rodney S, Banerji U. Optimizing the FDA\u2019s Project Optimus: opportunities and challenges. Nat Rev Clin Oncol. 2024;21(3):165\u20136.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"1492_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2165\/00003088-199121040-00002","volume":"21","author":"WJ van der Vijgh","year":"1991","unstructured":"van der Vijgh WJ. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet. 1991;21(4):242\u201361.","journal-title":"Clin Pharmacokinet"},{"key":"1492_CR12","unstructured":"FDA. Food and Drug Administration - Cisplatin injection - Product information. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/018057s092lbl.pdf. Accessed 05 Dec 2024."},{"key":"1492_CR13","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","volume":"135","author":"F Griesinger","year":"2019","unstructured":"Griesinger F, Korol EE, Kayaniyil S, Varol N, Ebner T, Goring SM. Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis. Lung Cancer. 2019;135:196\u2013204.","journal-title":"Lung Cancer"},{"issue":"8","key":"1492_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.18895","volume":"4","author":"CH Chen","year":"2021","unstructured":"Chen CH, Huang CY, Lin HH, Wang MC, Chang CY, Cheng YF. Association of sodium thiosulfate with risk of ototoxic effects from platinum-based chemotherapy: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(8): e2118895.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"1492_CR15","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.it.2010.05.006","volume":"31","author":"C Summers","year":"2010","unstructured":"Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. Neutrophil kinetics in health and disease. Trends Immunol. 2010;31(8):318\u201324.","journal-title":"Trends Immunol"},{"issue":"18","key":"1492_CR16","doi-asserted-by":"publisher","first-page":"5481","DOI":"10.1158\/1078-0432.CCR-06-0815","volume":"12","author":"C Kloft","year":"2006","unstructured":"Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res. 2006;12(18):5481\u201390.","journal-title":"Clin Cancer Res"},{"key":"1492_CR17","doi-asserted-by":"crossref","unstructured":"Wu YH, Chen HY, Hong WC, Wei CY, Pang JS. Carboplatin-induced thrombocytopenia through JAK2 downregulation, S-phase cell cycle arrest and apoptosis in megakaryocytes. Int J Mol Sci. 2022;23(11).","DOI":"10.3390\/ijms23116290"},{"issue":"11","key":"1492_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2217\/imt-2017-0052","volume":"9","author":"H Zheng","year":"2017","unstructured":"Zheng H, Zeltsman M, Zauderer MG, Eguchi T, Vaghjiani RG, Adusumilli PS. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. Immunotherapy. 2017;9(11):913\u201327.","journal-title":"Immunotherapy"},{"key":"1492_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.870178","volume":"13","author":"Z Zhou","year":"2022","unstructured":"Zhou Z, Zhao Y, Chen S, Cui G, Fu W, Li S, et al. Cisplatin promotes the efficacy of immune checkpoint inhibitor therapy by inducing ferroptosis and activating neutrophils. Front Pharmacol. 2022;13: 870178.","journal-title":"Front Pharmacol"},{"key":"1492_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.canlet.2020.11.049","volume":"500","author":"L Zhou","year":"2021","unstructured":"Zhou L, Xu Q, Huang L, Jin J, Zuo X, Zhang Q, et al. Low-dose carboplatin reprograms tumour immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer. Cancer Lett. 2021;500:163\u201371.","journal-title":"Cancer Lett"},{"issue":"5","key":"1492_CR21","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1021\/ed083p728","volume":"83","author":"RA Alderden","year":"2006","unstructured":"Alderden RA, Hall MD, Hambley TW. The discovery and development of cisplatin. J Chem Educ. 2006;83(5):728.","journal-title":"J Chem Educ"},{"issue":"12","key":"1492_CR22","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/bjc.1996.296","volume":"73","author":"JH Schellens","year":"1996","unstructured":"Schellens JH, Ma J, Planting AS, van der Burg ME, van Meerten E, de Boer-Dennert M, et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer. 1996;73(12):1569\u201375.","journal-title":"Br J Cancer"},{"issue":"4","key":"1492_CR23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1158\/1078-0432.CCR-18-2244","volume":"25","author":"MR Trendowski","year":"2019","unstructured":"Trendowski MR, El Charif O, Dinh PC Jr, Travis LB, Dolan ME. Genetic and modifiable risk factors contributing to cisplatin-induced toxicities. Clin Cancer Res. 2019;25(4):1147\u201355.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1492_CR24","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s00228-018-2552-z","volume":"75","author":"ME Ibrahim","year":"2019","unstructured":"Ibrahim ME, Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, et al. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. Eur J Clin Pharmacol. 2019;75(1):51\u20137.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"1492_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","volume":"22","author":"DJ Crona","year":"2017","unstructured":"Crona DJ, Faso A, Nishijima TF, McGraw KA, Galsky MD, Milowsky MI. A systematic review of strategies to prevent cisplatin-induced nephrotoxicity. Oncologist. 2017;22(5):609\u201319.","journal-title":"Oncologist"},{"issue":"6","key":"1492_CR26","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1002\/ana.24951","volume":"81","author":"NP Staff","year":"2017","unstructured":"Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol. 2017;81(6):772\u201381.","journal-title":"Ann Neurol"},{"issue":"7","key":"1492_CR27","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/bjc.2012.357","volume":"107","author":"E Chatelut","year":"2012","unstructured":"Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A. Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents. Br J Cancer. 2012;107(7):1100\u20136.","journal-title":"Br J Cancer"},{"key":"1492_CR28","unstructured":"ADDIKD. International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction. Sandhu G, Adattini J, Armstrong Gordon E, O\u2019Neill N. on behalf of the ADDIKD Guideline Working Group. 2022. https:\/\/www.eviq.org.au\/clinical-resources\/addikd-guideline\/4174-anticancer-drug-dosing-in-kidney-dysfunction. Accessed 03 Feb 2025."},{"issue":"2","key":"1492_CR29","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11096-013-9912-7","volume":"36","author":"Y Bennis","year":"2014","unstructured":"Bennis Y, Savry A, Rocca M, Gauthier-Villano L, Pisano P, Pourroy B. Cisplatin dose adjustment in patients with renal impairment, which recommendations should we follow? Int J Clin Pharm. 2014;36(2):420\u20139.","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"1492_CR30","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/bco2.81","volume":"2","author":"T Murakami","year":"2021","unstructured":"Murakami T, Kikuchi E, Ide H, Umezawa Y, Takahashi T, Izawa M, et al. Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma. BJUI Compass. 2021;2(5):322\u201330.","journal-title":"BJUI Compass."},{"issue":"2","key":"1492_CR31","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/cpt.1483","volume":"106","author":"BI Dr\u00f6gem\u00f6ller","year":"2019","unstructured":"Dr\u00f6gem\u00f6ller BI, Wright GEB, Lo C, Le T, Brooks B, Bhavsar AP, et al. Pharmacogenomics of cisplatin-induced ototoxicity: successes, shortcomings, and future avenues of research. Clin Pharmacol Ther. 2019;106(2):350\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1492_CR32","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.3389\/fphar.2018.01111","volume":"9","author":"Z Zazuli","year":"2018","unstructured":"Zazuli Z, Vijverberg S, Slob E, Liu G, Carleton B, Veltman J, et al. Genetic variations and cisplatin nephrotoxicity: a systematic review. Front Pharmacol. 2018;9:1111.","journal-title":"Front Pharmacol"},{"key":"1492_CR33","unstructured":"Zazuli Z, de Jong C, Xu W, Vijverberg SJH, Masereeuw R, Patel D, et al. Association between genetic variants and cisplatin-induced nephrotoxicity: a genome-wide approach and validation study. J Pers Med. 2021;11(11)."},{"issue":"9","key":"1492_CR34","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(05)70255-2","volume":"6","author":"M Di Maio","year":"2005","unstructured":"Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S, et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol. 2005;6(9):669\u201377.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1492_CR35","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/17425255.2020.1789590","volume":"16","author":"M Maillard","year":"2020","unstructured":"Maillard M, Le Louedec F, Thomas F, Chatelut E. Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review. Expert Opin Drug Metab Toxicol. 2020;16(10):907\u201325.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"1492_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1046\/j.1365-2710.2003.00468.x","volume":"28","author":"S Monjanel-Mouterde","year":"2003","unstructured":"Monjanel-Mouterde S, Ciccolini J, Bagarry D, Zonta-David M, Duffaud F, Favre R, Durand A. Population pharmacokinetics of cisplatin after 120-h infusion: application to routine adaptive control with feedback. J Clin Pharm Ther. 2003;28(2):109\u201316.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"1492_CR37","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1097\/00007691-200608000-00008","volume":"28","author":"S Salas","year":"2006","unstructured":"Salas S, Mercier C, Ciccolini J, Pourroy B, Fanciullino R, Tranchand B, et al. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma. Ther Drug Monit. 2006;28(4):532\u20139.","journal-title":"Ther Drug Monit"},{"issue":"2","key":"1492_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1200\/JCO.1987.5.2.169","volume":"5","author":"DD Von Hoff","year":"1987","unstructured":"Von Hoff DD. Whither carboplatin?\u2014a replacement for or an alternative to cisplatin? J Clin Oncol. 1987;5(2):169\u201371.","journal-title":"J Clin Oncol"},{"key":"1492_CR39","unstructured":"FDA. Food and Drug Administration - Carboplatin injection - Product information. 2011. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/077139Orig1s016lbl.pdf. Accessed 05 Dec 2024."},{"issue":"11","key":"1492_CR40","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7(11):1748\u201356.","journal-title":"J Clin Oncol"},{"key":"1492_CR41","doi-asserted-by":"crossref","unstructured":"Wiltshaw E. Ovarian trials at the Royal Marsden. Cancer Treat Rev. 1985;12 Suppl A:67\u201371.","DOI":"10.1016\/0305-7372(85)90020-9"},{"issue":"23","key":"1492_CR42","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMra054415","volume":"354","author":"LA Stevens","year":"2006","unstructured":"Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473\u201383.","journal-title":"N Engl J Med"},{"issue":"1","key":"1492_CR43","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31\u201341.","journal-title":"Nephron"},{"issue":"21","key":"1492_CR44","doi-asserted-by":"publisher","first-page":"6502","DOI":"10.1158\/1078-0432.CCR-05-1076","volume":"12","author":"C Ekhart","year":"2006","unstructured":"Ekhart C, de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH. Flat dosing of carboplatin is justified in adult patients with normal renal function. Clin Cancer Res. 2006;12(21):6502\u20138.","journal-title":"Clin Cancer Res"},{"issue":"9\u201310","key":"1492_CR45","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1159\/000533173","volume":"52","author":"S De Rosa","year":"2023","unstructured":"De Rosa S, Greco M, Rauseo M, Annetta MG. The good, the bad, and the serum creatinine: exploring the effect of muscle mass and nutrition. Blood Purif. 2023;52(9\u201310):775\u201385.","journal-title":"Blood Purif"},{"issue":"1","key":"1492_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00280-017-3326-5","volume":"80","author":"M Bretagne","year":"2017","unstructured":"Bretagne M, Jouinot A, Durand JP, Huillard O, Boudou Rouquette P, Tlemsani C, et al. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity. Cancer Chemother Pharmacol. 2017;80(1):45\u201353.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1492_CR47","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00280-005-0012-9","volume":"57","author":"JD Herrington","year":"2006","unstructured":"Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia. Cancer Chemother Pharmacol. 2006;57(2):241\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1492_CR48","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/j.1445-5994.1996.tb01925.x","volume":"26","author":"MJ Millward","year":"1996","unstructured":"Millward MJ, Webster LK, Toner GC, Bishop JF, Rischin D, Stokes KH, et al. Carboplatin dosing based on measurement of renal function\u2013experience at the Peter MacCallum Cancer Institute. Aust N Z J Med. 1996;26(3):372\u20139.","journal-title":"Aust N Z J Med"},{"issue":"4","key":"1492_CR49","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00280-008-0787-6","volume":"63","author":"SV Picton","year":"2009","unstructured":"Picton SV, Keeble J, Holden V, Errington J, Boddy AV, Veal GJ. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma. Cancer Chemother Pharmacol. 2009;63(4):749\u201352.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"1492_CR50","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.ejca.2015.07.011","volume":"51","author":"GJ Veal","year":"2015","unstructured":"Veal GJ, Errington J, Hayden J, Hobin D, Murphy D, Dommett RM, et al. Carboplatin therapeutic monitoring in preterm and full-term neonates. Eur J Cancer. 2015;51(14):2022\u201330.","journal-title":"Eur J Cancer"},{"issue":"23","key":"1492_CR51","doi-asserted-by":"publisher","first-page":"7171","DOI":"10.1158\/1078-0432.CCR-17-1344","volume":"23","author":"S Moeung","year":"2017","unstructured":"Moeung S, Chevreau C, Broutin S, Guitton J, Leli\u00e8vre B, Ciccolini J, et al. Therapeutic drug monitoring of carboplatin in high-dose protocol (TI-CE) for advanced germ cell tumours: pharmacokinetic results of a phase II multicenter study. Clin Cancer Res. 2017;23(23):7171\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1492_CR52","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1159\/000516170","volume":"66","author":"A Le Bozec","year":"2021","unstructured":"Le Bozec A, Boulanger C, Mongaret C, Mar\u00e9chal A, Dewolf M, Slimano F. Safety and survival outcomes in lung cancer patients receiving carboplatin: impact of uncapped dosage. Chemotherapy. 2021;66(3):72\u20137.","journal-title":"Chemotherapy"},{"issue":"30","key":"1492_CR53","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1200\/JCO.2010.29.3597","volume":"28","author":"A Schmitt","year":"2010","unstructured":"Schmitt A, Gladieff L, Laffont CM, Evrard A, Boyer J-C, Lansiaux A, et al. Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure. J Clin Oncol. 2010;28(30):4568\u201374.","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"1492_CR54","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.injury.2022.05.004","volume":"53","author":"L Ackermans","year":"2022","unstructured":"Ackermans L, Volmer L, Timmermans Q, Brecheisen R, Damink S, Dekker A, et al. Clinical evaluation of automated segmentation for body composition analysis on abdominal L3 CT slices in polytrauma patients. Injury. 2022;53(Suppl 3):S30-s41.","journal-title":"Injury"},{"issue":"1","key":"1492_CR55","doi-asserted-by":"publisher","first-page":"9013","DOI":"10.1038\/s41598-022-13145-w","volume":"12","author":"TT Pieters","year":"2022","unstructured":"Pieters TT, Veldhuis WB, Moeskops P, de Vos BD, Verhaar MC, Haitjema S, et al. Deep learning body-composition analysis of clinically acquired CT-scans estimates creatinine excretion with high accuracy in patients and healthy individuals. Sci Rep. 2022;12(1):9013.","journal-title":"Sci Rep"},{"issue":"3","key":"1492_CR56","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/SHK.0000000000001510","volume":"54","author":"R Beunders","year":"2020","unstructured":"Beunders R, van Groenendael R, Leijte GP, Kox M, Pickkers P. Proenkephalin compared to conventional methods to assess kidney function in critically ill sepsis patients. Shock. 2020;54(3):308\u201314.","journal-title":"Shock"},{"issue":"19","key":"1492_CR57","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin c-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737\u201349.","journal-title":"N Engl J Med"},{"issue":"10","key":"1492_CR58","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1158\/1078-0432.CCR-09-0017","volume":"15","author":"A Schmitt","year":"2009","unstructured":"Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, et al. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res. 2009;15(10):3633\u20139.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1492_CR59","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.2165\/00003088-200544120-00009","volume":"44","author":"F Thomas","year":"2005","unstructured":"Thomas F, S\u00e9ronie-Vivien S, Gladieff L, Dalenc F, Durrand V, Malard L, et al. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin. Clin Pharmacokinet. 2005;44(12):1305\u201316.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1492_CR60","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s00280-019-04020-z","volume":"85","author":"M White-Koning","year":"2020","unstructured":"White-Koning M, Paludetto MN, Le Louedec F, Gladieff L, Chevreau C, Chatelut E, Puisset F. Formulae recently proposed to estimate renal glomerular filtration rate improve the prediction of carboplatin clearance. Cancer Chemother Pharmacol. 2020;85(3):585\u201392.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"1492_CR61","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1517\/17425255.2011.587411","volume":"7","author":"JB S\u00f8rensen","year":"2011","unstructured":"S\u00f8rensen JB. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol. 2011;7(7):919\u201328.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"1492_CR62","first-page":"1116","volume":"57","author":"C Shih","year":"1997","unstructured":"Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997;57(6):1116\u201323.","journal-title":"Cancer Res"},{"key":"1492_CR63","doi-asserted-by":"crossref","unstructured":"Lu CS, Lin CW, Chang YH, Chen HY, Chung WC, Lai WY, et al. Antimetabolite pemetrexed primes a favorable tumour microenvironment for immune checkpoint blockade therapy. J Immunother Cancer. 2020;8(2).","DOI":"10.1136\/jitc-2020-001392"},{"issue":"22","key":"1492_CR64","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, Rodr\u00edguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"4","key":"1492_CR65","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","volume":"16","author":"M Nishio","year":"2021","unstructured":"Nishio M, Barlesi F, West H, Ball S, Bordoni R, Cobo M, et al. Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial. J Thorac Oncol. 2021;16(4):653\u201364.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"1492_CR66","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00280-005-0036-1","volume":"57","author":"JE Latz","year":"2006","unstructured":"Latz JE, Chaudhary A, Ghosh A, Johnson RD. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol. 2006;57(4):401\u201311.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1492_CR67","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00280-016-3078-7","volume":"78","author":"Y Ando","year":"2016","unstructured":"Ando Y, Hayashi T, Ujita M, Murai S, Ohta H, Ito K, et al. Effect of renal function on pemetrexed-induced haematotoxicity. Cancer Chemother Pharmacol. 2016;78(1):183\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1492_CR68","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00280-005-0035-2","volume":"57","author":"JE Latz","year":"2006","unstructured":"Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD. Clinical application of a semimechanistic-physiologic population PK\/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol. 2006;57(4):427\u201335.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1492_CR69","unstructured":"FDA. Food and Drug Administration - ALIMTA (pemetrexed disodium) Injection - Product information. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021462s021lbl.pdf. Accessed 05 Dec 2024."},{"issue":"5","key":"1492_CR70","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1093\/annonc\/mdf115","volume":"13","author":"SJ Clarke","year":"2002","unstructured":"Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-na\u00efve patients with advanced non-small-cell lung cancer. Ann Oncol. 2002;13(5):737\u201341.","journal-title":"Ann Oncol"},{"key":"1492_CR71","doi-asserted-by":"crossref","unstructured":"Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17(4):1194.","DOI":"10.1200\/JCO.1999.17.4.1194"},{"issue":"2","key":"1492_CR72","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100(2):228\u201337.","journal-title":"Cancer"},{"issue":"7","key":"1492_CR73","first-page":"545","volume":"1","author":"C Niyikiza","year":"2002","unstructured":"Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther. 2002;1(7):545\u201352.","journal-title":"Mol Cancer Ther"},{"issue":"23","key":"1492_CR74","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","volume":"31","author":"LG Paz-Ares","year":"2013","unstructured":"Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013;31(23):2895\u2013902.","journal-title":"J Clin Oncol"},{"key":"1492_CR75","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2019.08.012","volume":"121","author":"S Visser","year":"2019","unstructured":"Visser S, Koolen SLW, de Bruijn P, Belderbos HNA, Cornelissen R, Mathijssen RHJ, et al. Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: a prospective cohort study. Eur J Cancer. 2019;121:64\u201373.","journal-title":"Eur J Cancer"},{"issue":"8","key":"1492_CR76","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1002\/ijc.33721","volume":"149","author":"RJ Boosman","year":"2021","unstructured":"Boosman RJ, Dorlo TPC, de Rouw N, Burgers JA, Dingemans AC, van den Heuvel MM, et al. Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment. Int J Cancer. 2021;149(8):1576\u201384.","journal-title":"Int J Cancer"},{"issue":"12","key":"1492_CR77","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJM197709222971203","volume":"297","author":"RG Stoller","year":"1977","unstructured":"Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977;297(12):630\u20134.","journal-title":"N Engl J Med"},{"issue":"5","key":"1492_CR78","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/03007995.2018.1439462","volume":"34","author":"G Middleton","year":"2018","unstructured":"Middleton G, Gridelli C, De Marinis F, Pujol JL, Reck M, Ramlau R, et al. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Curr Med Res Opin. 2018;34(5):865\u201371.","journal-title":"Curr Med Res Opin"},{"key":"1492_CR79","doi-asserted-by":"crossref","unstructured":"Visser S, Huisbrink J, van 't Veer NE, van Toor JJ, van Boxem AJM, van Walree NC, et al. Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. Eur Respir J. 2018;52(4).","DOI":"10.1183\/13993003.00884-2018"},{"issue":"4","key":"1492_CR80","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","volume":"24","author":"AC Mita","year":"2006","unstructured":"Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, et al. Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. 2006;24(4):552\u201362.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1492_CR81","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s40264-021-01135-2","volume":"44","author":"N de Rouw","year":"2021","unstructured":"de Rouw N, Piet B, Derijks HJ, van den Heuvel MM, Ter Heine R. Mechanisms, management and prevention of pemetrexed-related toxicity. Drug Saf. 2021;44(12):1271\u201381.","journal-title":"Drug Saf"},{"issue":"5","key":"1492_CR82","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/annonc\/mdm592","volume":"19","author":"MH Cullen","year":"2008","unstructured":"Cullen MH, Zatloukal P, S\u00f6renson S, Novello S, Fischer JR, Joy AA, et al. A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2008;19(5):939\u201345.","journal-title":"Ann Oncol"},{"key":"1492_CR83","doi-asserted-by":"crossref","unstructured":"Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, et al. A randomized phase II study of 500 mg\/m2 and 1,000 mg\/m2 of pemetrexed in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had prior chemotherapy. J Clin Oncol. 2007;25(18_suppl):7590.","DOI":"10.1200\/jco.2007.25.18_suppl.7590"},{"issue":"9","key":"1492_CR84","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","volume":"22","author":"N Hanna","year":"2004","unstructured":"Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589\u201397.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1492_CR85","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/cpt.2529","volume":"111","author":"N de Rouw","year":"2022","unstructured":"de Rouw N, de Boer M, Boosman RJ, van den Heuvel MM, Burger DM, Lieverse JE, et al. The pharmacoeconomic benefits of pemetrexed dose individualization in patients with lung cancer. Clin Pharmacol Ther. 2022;111(5):1103\u201310.","journal-title":"Clin Pharmacol Ther"},{"key":"1492_CR86","doi-asserted-by":"crossref","unstructured":"de Rouw N, Beunders R, Hartmann O, Schulte J, Boosman RJ, Derijks HJ, et al. A comparison of the renal function biomarkers serum creatinine, pro-enkephalin and cystatin C to predict clearance of pemetrexed. Cancer Chemother Pharmacol. 2024.","DOI":"10.1007\/s00280-024-04717-w"},{"issue":"1","key":"1492_CR87","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00280-019-04006-x","volume":"85","author":"N de Rouw","year":"2020","unstructured":"de Rouw N, Visser S, Koolen SLW, Aerts J, van den Heuvel MM, Derijks HJ, et al. A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions. Cancer Chemother Pharmacol. 2020;85(1):231\u20135.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"45","key":"1492_CR88","doi-asserted-by":"publisher","first-page":"16219","DOI":"10.1073\/pnas.1408886111","volume":"111","author":"R Zhang","year":"2014","unstructured":"Zhang R, Lahens NF, Ballance HI, Hughes ME, Hogenesch JB. A circadian gene expression atlas in mammals: implications for biology and medicine. Proc Natl Acad Sci U S A. 2014;111(45):16219\u201324.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1492_CR89","doi-asserted-by":"crossref","unstructured":"Sun L-Y, Xu Q-A, Xu X, Xian K-X, Zeng X-X, Li H-G, Zhang X-H. Efficacy and safety of time-of-day infusion of pemetrexed plus platinum and paclitaxel plus platinum for patients with advanced non-small cell lung cancer: a retrospective study. J Clin Oncol. 2024;42(16_suppl):e20557-e.","DOI":"10.1200\/JCO.2024.42.16_suppl.e20557"},{"key":"1492_CR90","first-page":"405","volume":"148","author":"Y Li","year":"2015","unstructured":"Li Y, Zhang G, Pfeifer BA. Current and emerging options for taxol production. Adv Biochem Eng Biotechnol. 2015;148:405\u201325.","journal-title":"Adv Biochem Eng Biotechnol"},{"key":"1492_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2020.100742","volume":"54","author":"L Mosca","year":"2021","unstructured":"Mosca L, Ilari A, Fazi F, Assaraf YG, Colotti G. Taxanes in cancer treatment: activity, chemoresistance and its overcoming. Drug Resist Updat. 2021;54: 100742.","journal-title":"Drug Resist Updat"},{"issue":"2","key":"1492_CR92","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00003088-199936020-00002","volume":"36","author":"SJ Clarke","year":"1999","unstructured":"Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet. 1999;36(2):99\u2013114.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1492_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00001813-199801000-00001","volume":"9","author":"A Sparreboom","year":"1998","unstructured":"Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs. 1998;9(1):1\u201317.","journal-title":"Anticancer Drugs"},{"issue":"12","key":"1492_CR94","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.1994.12.12.2654","volume":"12","author":"EA Eisenhauer","year":"1994","unstructured":"Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 1994;12(12):2654\u201366.","journal-title":"J Clin Oncol"},{"key":"1492_CR95","unstructured":"EMA. European Medicines Agency - TAXOTERE (INN-docetaxel) - Product information (EPAR). 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/taxotere-epar-product-information_en.pdf. Accessed 05 Dec 2024."},{"issue":"2","key":"1492_CR96","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/bcp.14678","volume":"87","author":"M Muth","year":"2021","unstructured":"Muth M, Ojara FW, Kloft C, Joerger M. Role of TDM-based dose adjustments for taxane anticancer drugs. Br J Clin Pharmacol. 2021;87(2):306\u201316.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"1492_CR97","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jtho.2021.03.027","volume":"16","author":"Y Yoneshima","year":"2021","unstructured":"Yoneshima Y, Morita S, Ando M, Nakamura A, Iwasawa S, Yoshioka H, et al. Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC. J Thorac Oncol. 2021;16(9):1523\u201332.","journal-title":"J Thorac Oncol"},{"issue":"17","key":"1492_CR98","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","volume":"30","author":"MA Socinski","year":"2012","unstructured":"Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055\u201362.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1492_CR99","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41419-020-2567-0","volume":"11","author":"AF Serpico","year":"2020","unstructured":"Serpico AF, Visconti R, Grieco D. Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment. Cell Death Dis. 2020;11(5):361.","journal-title":"Cell Death Dis"},{"key":"1492_CR100","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/413076","volume":"2015","author":"NC Kampan","year":"2015","unstructured":"Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M. Paclitaxel and its evolving role in the management of ovarian cancer. Biomed Res Int. 2015;2015: 413076.","journal-title":"Biomed Res Int"},{"issue":"3\u20134","key":"1492_CR101","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000236016","volume":"77","author":"M Muta","year":"2009","unstructured":"Muta M, Yanagawa T, Sai Y, Saji S, Suzuki E, Aruga T, et al. Effect of low-dose paclitaxel and docetaxel on endothelial progenitor cells. Oncology. 2009;77(3\u20134):182\u201391.","journal-title":"Oncology"},{"issue":"2","key":"1492_CR102","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/BF00210785","volume":"14","author":"S Urien","year":"1996","unstructured":"Urien S, Barr\u00e9 J, Morin C, Paccaly A, Montay G, Tillement JP. Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein. Invest New Drugs. 1996;14(2):147\u201351.","journal-title":"Invest New Drugs"},{"issue":"2","key":"1492_CR103","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF02353487","volume":"24","author":"R Bruno","year":"1996","unstructured":"Bruno R, Vivier N, Vergniol JC, De Phillips SL, Montay G, Sheiner LB. A population pharmacokinetic model for docetaxel (Taxotere): model building and validation. J Pharmacokinet Biopharm. 1996;24(2):153\u201372.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"8","key":"1492_CR104","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.ejca.2003.12.026","volume":"40","author":"MA Rudek","year":"2004","unstructured":"Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer. 2004;40(8):1170\u20138.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1492_CR105","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1998.16.1.187","volume":"16","author":"R Bruno","year":"1998","unstructured":"Bruno R, Hille D, Riva A, Vivier N, ten Bokkel Huinnink WW, van Oosterom AT, et al. Population pharmacokinetics\/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol. 1998;16(1):187\u201396.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1492_CR106","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1111\/bcp.14614","volume":"87","author":"A Lombard","year":"2021","unstructured":"Lombard A, Mistry H, Aarons L, Ogungbenro K. Dose individualisation in oncology using chemotherapy-induced neutropenia: example of docetaxel in non-small cell lung cancer patients. Br J Clin Pharmacol. 2021;87(4):2053\u201363.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1492_CR107","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.lungcan.2008.03.030","volume":"62","author":"AG Pallis","year":"2008","unstructured":"Pallis AG, Agelaki S, Kakolyris S, Kotsakis A, Kalykaki A, Vardakis N, et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy. Lung Cancer. 2008;62(3):356\u201363.","journal-title":"Lung Cancer"},{"issue":"19","key":"1492_CR108","doi-asserted-by":"publisher","first-page":"5786","DOI":"10.1158\/1078-0432.CCR-05-2649","volume":"12","author":"TM Bosch","year":"2006","unstructured":"Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res. 2006;12(19):5786\u201393.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1492_CR109","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.clpt.2006.02.003","volume":"79","author":"A Tran","year":"2006","unstructured":"Tran A, Jullien V, Alexandre J, Rey E, Rabillon F, Girre V, et al. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms. Clin Pharmacol Ther. 2006;79(6):570\u201380.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"1492_CR110","first-page":"1255","volume":"6","author":"J Hirth","year":"2000","unstructured":"Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual\u2019s cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res. 2000;6(4):1255\u20138.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"1492_CR111","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s00280-010-1426-6","volume":"67","author":"J Hilli","year":"2011","unstructured":"Hilli J, Sailas L, Jyrkki\u00f6 S, Pyrh\u00f6nen S, Laine K. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer. Cancer Chemother Pharmacol. 2011;67(6):1353\u201362.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"1492_CR112","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s00280-011-1609-9","volume":"68","author":"WC Zamboni","year":"2011","unstructured":"Zamboni WC, Combest AJ, DeLoia JA, Edwards RP, Bridges AS, Zamboni BA, et al. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. Cancer Chemother Pharmacol. 2011;68(5):1255\u201362.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"1492_CR113","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1200\/JCO.2000.18.11.2301","volume":"18","author":"N Yamamoto","year":"2000","unstructured":"Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J Clin Oncol. 2000;18(11):2301\u20138.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1492_CR114","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2005.11.036","volume":"23","author":"N Yamamoto","year":"2005","unstructured":"Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y, et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005;23(6):1061\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1492_CR115","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/bcp.15987","volume":"90","author":"R Hirano","year":"2024","unstructured":"Hirano R, Yokokawa A, Furihata T, Shibasaki H. Plasma 6\u03b2-hydroxycortisol to cortisol ratio as a less invasive cytochrome P450 3A phenotyping method. Br J Clin Pharmacol. 2024;90(4):1016\u201326.","journal-title":"Br J Clin Pharmacol"},{"key":"1492_CR116","doi-asserted-by":"crossref","unstructured":"Heerma van Voss MR, Notohardjo J, van Dodewaard-de Jong J, Bloemendal HJ, Heine RT. A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients. Cancer Chemother Pharmacol. 2024.","DOI":"10.1007\/s00280-024-04684-2"},{"issue":"4","key":"1492_CR117","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00280-015-2844-2","volume":"76","author":"K Fujita","year":"2015","unstructured":"Fujita K, Yoshino E, Kawara K, Maeda K, Kusuhara H, Sugiyama Y, et al. A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer. Cancer Chemother Pharmacol. 2015;76(4):793\u2013801.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1492_CR118","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ctrv.2006.07.003","volume":"32","author":"E Bria","year":"2006","unstructured":"Bria E, Cuppone F, Ciccarese M, Nistic\u00f2 C, Facciolo F, Milella M, et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev. 2006;32(8):583\u20137.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"1492_CR119","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1158\/1078-0432.CCR-10-1636","volume":"17","author":"FK Engels","year":"2011","unstructured":"Engels FK, Loos WJ, van der Bol JM, de Bruijn P, Mathijssen RH, Verweij J, Mathot RA. Therapeutic drug monitoring for the individualization of docetaxel dosing: a randomized pharmacokinetic study. Clin Cancer Res. 2011;17(2):353\u201362.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1492_CR120","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1002\/cam4.2003","volume":"8","author":"AHM de Vries Schultink","year":"2019","unstructured":"de Vries Schultink AHM, Crombag MBS, van Werkhoven E, Otten HM, Bergman AM, Schellens JHM, et al. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: a meta-analysis and evaluation of a clinical cohort. Cancer Med. 2019;8(4):1406\u201315.","journal-title":"Cancer Med"},{"issue":"3","key":"1492_CR121","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1742-7843.2009.00520.x","volume":"106","author":"JE Wallin","year":"2010","unstructured":"Wallin JE, Friberg LE, Karlsson MO. Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information. Basic Clin Pharmacol Toxicol. 2010;106(3):234\u201342.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"1492_CR122","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40262-017-0563-z","volume":"57","author":"TB Stage","year":"2018","unstructured":"Stage TB, Bergmann TK, Kroetz DL. Clinical pharmacokinetics of paclitaxel monotherapy: an updated literature review. Clin Pharmacokinet. 2018;57(1):7\u201319.","journal-title":"Clin Pharmacokinet"},{"key":"1492_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114024","volume":"202","author":"DL Hertz","year":"2024","unstructured":"Hertz DL, Joerger M, Bang YJ, Mathijssen RH, Zhou C, Zhang L, et al. Paclitaxel therapeutic drug monitoring\u2014international association of therapeutic drug monitoring and clinical toxicology recommendations. Eur J Cancer. 2024;202: 114024.","journal-title":"Eur J Cancer"},{"key":"1492_CR124","doi-asserted-by":"crossref","unstructured":"Huizing MT, Giaccone G, van Warmerdam LJ, Rosing H, Bakker PJ, Vermorken JB, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol. 1997;15(1):317\u201329.","DOI":"10.1200\/JCO.1997.15.1.317"},{"issue":"5","key":"1492_CR125","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/j.1365-2125.2007.02956.x","volume":"64","author":"M Joerger","year":"2007","unstructured":"Joerger M, Huitema AD, Huizing MT, Willemse PH, de Graeff A, Rosing H, et al. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study. Br J Clin Pharmacol. 2007;64(5):622\u201333.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"1492_CR126","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1517\/14740338.2010.487063","volume":"9","author":"MY Biakhov","year":"2010","unstructured":"Biakhov MY, Kononova GV, Iglesias J, Desai N, Bhar P, Schmid AN, Loibl S. nab-Paclitaxel in patients with advanced solid tumours and hepatic dysfunction: a pilot study. Expert Opin Drug Saf. 2010;9(4):515\u201323.","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"1492_CR127","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/jcph.304","volume":"54","author":"N Chen","year":"2014","unstructured":"Chen N, Li Y, Ye Y, Palmisano M, Chopra R, Zhou S. Pharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumours: disposition kinetics and pharmacology distinct from solvent-based paclitaxel. J Clin Pharmacol. 2014;54(10):1097\u2013107.","journal-title":"J Clin Pharmacol"},{"issue":"7 Pt 1","key":"1492_CR128","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1158\/1078-0432.CCR-05-2069","volume":"12","author":"M Joerger","year":"2006","unstructured":"Joerger M, Huitema AD, van den Bongard DH, Schellens JH, Beijnen JH. Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumours. Clin Cancer Res. 2006;12(7 Pt 1):2150\u20137.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1492_CR129","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1517\/17425255.2015.983074","volume":"11","author":"M Joerger","year":"2015","unstructured":"Joerger M. Metabolism of the taxanes including nab-paclitaxel. Expert Opin Drug Metab Toxicol. 2015;11(5):691\u2013702.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1492_CR130","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.critrevonc.2019.04.021","volume":"139","author":"X Guo","year":"2019","unstructured":"Guo X, Sun H, Dong J, Feng Y, Li H, Zhuang R, et al. Does nab-paclitaxel have a higher incidence of peripheral neuropathy than solvent-based paclitaxel? Evidence from a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2019;139:16\u201323.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"1492_CR131","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/tpj.2010.19","volume":"11","author":"TK Bergmann","year":"2011","unstructured":"Bergmann TK, Brasch-Andersen C, Gr\u00e9en H, Mirza M, Pedersen RS, Nielsen F, et al. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenom J. 2011;11(2):113\u201320.","journal-title":"Pharmacogenom J"},{"issue":"1","key":"1492_CR132","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10549-012-2054-0","volume":"134","author":"DL Hertz","year":"2012","unstructured":"Hertz DL, Motsinger-Reif AA, Drobish A, Winham SJ, McLeod HL, Carey LA, Dees EC. CYP2C8*3 predicts benefit\/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat. 2012;134(1):401\u201310.","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"1492_CR133","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.ejca.2006.06.017","volume":"42","author":"TM Sissung","year":"2006","unstructured":"Sissung TM, Mross K, Steinberg SM, Behringer D, Figg WD, Sparreboom A, Mielke S. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer. 2006;42(17):2893\u20136.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1492_CR134","first-page":"271","volume":"23","author":"H Chang","year":"2010","unstructured":"Chang H, Rha SY, Jeung HC, Im CK, Noh SH, Kim JJ, Chung HC. Association of the ABCB1 3435C>T polymorphism and treatment outcomes in advanced gastric cancer patients treated with paclitaxel-based chemotherapy. Oncol Rep. 2010;23(1):271\u20138.","journal-title":"Oncol Rep"},{"issue":"6","key":"1492_CR135","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.ctrv.2011.10.008","volume":"38","author":"TC Huang","year":"2012","unstructured":"Huang TC, Campbell TC. Comparison of weekly versus every 3 weeks paclitaxel in the treatment of advanced solid tumours: a meta-analysis. Cancer Treat Rev. 2012;38(6):613\u20137.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"1492_CR136","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1097\/JTO.0b013e3181d5e39e","volume":"5","author":"MA Socinski","year":"2010","unstructured":"Socinski MA, Manikhas GM, Stroyakovsky DL, Makhson AN, Cheporov SV, Orlov SV, et al. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(6):852\u201361.","journal-title":"J Thorac Oncol"},{"issue":"22","key":"1492_CR137","doi-asserted-by":"publisher","first-page":"3611","DOI":"10.1200\/JCO.2008.18.5397","volume":"27","author":"WJ Gradishar","year":"2009","unstructured":"Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A, Bhar P. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009;27(22):3611\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1492_CR138","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00280-020-04110-3","volume":"86","author":"M Kan","year":"2020","unstructured":"Kan M, Imaoka H, Watanabe K, Sasaki M, Takahashi H, Hashimoto Y, et al. Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study. Cancer Chemother Pharmacol. 2020;86(2):203\u201310.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1492_CR139","doi-asserted-by":"publisher","first-page":"469","DOI":"10.21037\/jgo.2016.01.03","volume":"7","author":"W Scheithauer","year":"2016","unstructured":"Scheithauer W, Ramanathan RK, Moore M, Macarulla T, Goldstein D, Hammel P, et al. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol. 2016;7(3):469\u201378.","journal-title":"J Gastrointest Oncol."},{"issue":"6","key":"1492_CR140","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/FTD.0000000000000446","volume":"39","author":"M Joerger","year":"2017","unstructured":"Joerger M, Kraff S, Jaehde U, Hilger RA, Courtney JB, Cline DJ, et al. Validation of a commercial assay and decision support tool for routine paclitaxel therapeutic drug monitoring (TDM). Ther Drug Monit. 2017;39(6):617\u201324.","journal-title":"Ther Drug Monit"},{"issue":"Suppl 5","key":"1492_CR141","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","volume":"17","author":"E Mini","year":"2006","unstructured":"Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17(Suppl 5):v7-12.","journal-title":"Ann Oncol"},{"issue":"1","key":"1492_CR142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00280-016-3003-0","volume":"78","author":"J Ciccolini","year":"2016","unstructured":"Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol. 2016;78(1):1\u201312.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1492_CR143","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1179\/joc.2007.19.2.212","volume":"19","author":"GJ Peters","year":"2007","unstructured":"Peters GJ, Clavel M, Noordhuis P, Geyssen GJ, Laan AC, Guastalla J, et al. Clinical phase I and pharmacology study of gemcitabine (2\u2019, 2\u2019-difluorodeoxycytidine) administered in a two-weekly schedule. J Chemother. 2007;19(2):212\u201321.","journal-title":"J Chemother"},{"issue":"3","key":"1492_CR144","first-page":"533","volume":"52","author":"V Heinemann","year":"1992","unstructured":"Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W. Cellular elimination of 2\u2019,2\u2019-difluorodeoxycytidine 5\u2019-triphosphate: a mechanism of self-potentiation. Cancer Res. 1992;52(3):533\u20139.","journal-title":"Cancer Res"},{"issue":"4","key":"1492_CR145","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/BF00685109","volume":"27","author":"R Grunewald","year":"1991","unstructured":"Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2\u2019,2\u2019-difluorodeoxycytidine 5\u2019-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol. 1991;27(4):258\u201362.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"1492_CR146","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1158\/1535-7163.MCT-08-0137","volume":"7","author":"SA Veltkamp","year":"2008","unstructured":"Veltkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R, et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2\u2019,2\u2019-difluorodeoxyuridine. Mol Cancer Ther. 2008;7(8):2415\u201325.","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"1492_CR147","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2165\/11532970-000000000-00000","volume":"49","author":"E Sugiyama","year":"2010","unstructured":"Sugiyama E, Kaniwa N, Kim SR, Hasegawa R, Saito Y, Ueno H, et al. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. Clin Pharmacokinet. 2010;49(8):549\u201358.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1492_CR148","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00280-022-04431-5","volume":"89","author":"RJ Boosman","year":"2022","unstructured":"Boosman RJ, Crombag MBS, van Erp NP, Beijnen JH, Steeghs N, Huitema ADR. Is age just a number? A population pharmacokinetic study of gemcitabine. Cancer Chemother Pharmacol. 2022;89(5):697\u2013705.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"30","key":"1492_CR149","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.1002\/chem.200700260","volume":"13","author":"NM Cerqueira","year":"2007","unstructured":"Cerqueira NM, Fernandes PA, Ramos MJ. Understanding ribonucleotide reductase inactivation by gemcitabine. Chemistry. 2007;13(30):8507\u201315.","journal-title":"Chemistry"},{"issue":"6","key":"1492_CR150","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00280-012-1974-z","volume":"70","author":"MT Qiu","year":"2012","unstructured":"Qiu MT, Ding XX, Hu JW, Tian HY, Yin R, Xu L. Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials. Cancer Chemother Pharmacol. 2012;70(6):861\u201373.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1492_CR151","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00280-008-0885-5","volume":"64","author":"GW Lee","year":"2009","unstructured":"Lee GW, Kang MH, Kim HG, Kang JH, Kim SH, Cho YJ, et al. Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer. Cancer Chemother Pharmacol. 2009;64(2):385\u201390.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1492_CR152","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.critrevonc.2008.06.010","volume":"68","author":"C Locher","year":"2008","unstructured":"Locher C, Fabre-Guillevin E, Brunetti F, Auroux J, Delchier JC, Piedbois P, Zelek L. Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study. Crit Rev Oncol Hematol. 2008;68(2):178\u201382.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1492_CR153","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.eclinm.2019.03.011","volume":"9","author":"V Patil","year":"2019","unstructured":"Patil V, Noronha V, Joshi A, Chougule A, Kannan S, Bhattacharjee A, et al. Phase III non-inferiority study evaluating efficacy and safety of low dose gemcitabine compared to standard dose gemcitabine with platinum in advanced squamous lung cancer. EClinicalMedicine. 2019;9:19\u201325.","journal-title":"EClinicalMedicine."},{"issue":"10","key":"1492_CR154","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002936","volume":"95","author":"J Xiong","year":"2016","unstructured":"Xiong J, Altaf K, Ke N, Wang Y, Tang J, Tan C, et al. dCK expression and gene polymorphism with gemcitabine chemosensitivity in patients with pancreatic ductal adenocarcinoma: a strobe-compliant observational study. Medicine (Baltimore). 2016;95(10): e2936.","journal-title":"Medicine (Baltimore)"},{"issue":"26","key":"1492_CR155","doi-asserted-by":"publisher","first-page":"8482","DOI":"10.3748\/wjg.v20.i26.8482","volume":"20","author":"S Nordh","year":"2014","unstructured":"Nordh S, Ansari D, Andersson R. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review. World J Gastroenterol. 2014;20(26):8482\u201390.","journal-title":"World J Gastroenterol"},{"key":"1492_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00240","volume":"3","author":"LJ Vos","year":"2019","unstructured":"Vos LJ, Yusuf D, Lui A, Abdelaziz Z, Ghosh S, Spratlin JL, Mackey JR. Predictive and prognostic properties of human equilibrative nucleoside transporter 1 expression in gemcitabine-treated pancreatobiliary cancer: a meta-analysis. JCO Precis Oncol. 2019;3:1\u201322.","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"1492_CR157","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/FTD.0000000000000402","volume":"39","author":"D Kozo","year":"2017","unstructured":"Kozo D, Ross MW, Jarrah J, Barrett M, Harney RL, Courtney JB, et al. Rapid homogeneous immunoassay to quantify gemcitabine in plasma for therapeutic drug monitoring. Ther Drug Monit. 2017;39(3):235\u201342.","journal-title":"Ther Drug Monit"},{"issue":"11","key":"1492_CR158","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1023\/A:1013133415945","volume":"12","author":"S Fogli","year":"2001","unstructured":"Fogli S, Danesi R, De Braud F, De Pas T, Curigliano G, Giovannetti G, Del Tacca M. Drug distribution and pharmacokinetic\/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. Ann Oncol. 2001;12(11):1553\u20139.","journal-title":"Ann Oncol"},{"issue":"8","key":"1492_CR159","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.2174\/138945012802009017","volume":"13","author":"A Capasso","year":"2012","unstructured":"Capasso A. Vinorelbine in cancer therapy. Curr Drug Targets. 2012;13(8):1065\u201371.","journal-title":"Curr Drug Targets"},{"issue":"5 Suppl 10","key":"1492_CR160","first-page":"21","volume":"21","author":"WA Wargin","year":"1994","unstructured":"Wargin WA, Lucas VS. The clinical pharmacokinetics of vinorelbine (Navelbine). Semin Oncol. 1994;21(5 Suppl 10):21\u20137.","journal-title":"Semin Oncol"},{"issue":"16","key":"1492_CR161","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1200\/JCO.2005.02.1295","volume":"24","author":"M Wong","year":"2006","unstructured":"Wong M, Balleine RL, Blair EY, McLachlan AJ, Ackland SP, Garg MB, et al. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol. 2006;24(16):2448\u201355.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1492_CR162","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/14740331003774078","volume":"9","author":"MC Piccirillo","year":"2010","unstructured":"Piccirillo MC, Daniele G, Di Maio M, Bryce J, De Feo G, Del Giudice A, et al. Vinorelbine for non-small cell lung cancer. Expert Opin Drug Saf. 2010;9(3):493\u2013510.","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"1492_CR163","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S0090-9556(24)15196-3","volume":"28","author":"J Kajita","year":"2000","unstructured":"Kajita J, Kuwabara T, Kobayashi H, Kobayashi S. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos. 2000;28(9):1121\u20137.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"1492_CR164","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejca.2009.10.031","volume":"46","author":"JJ Kitzen","year":"2010","unstructured":"Kitzen JJ, Puozzo C, de Jonge MJ, Brandely M, Verweij J. Mild to moderate liver dysfunction does not require dose reduction of oral or intravenous vinorelbine: results of a pharmacokinetic study. Eur J Cancer. 2010;46(2):266\u20139.","journal-title":"Eur J Cancer"},{"issue":"1","key":"1492_CR165","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00280-005-0132-2","volume":"58","author":"AF Schott","year":"2006","unstructured":"Schott AF, Rae JM, Griffith KA, Hayes DF, Sterns V, Baker LH. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother Pharmacol. 2006;58(1):129\u201335.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"1492_CR166","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00280-018-3751-0","volume":"83","author":"M Gusella","year":"2019","unstructured":"Gusella M, Pasini F, Caruso D, Barile C, Modena Y, Fraccon AP, et al. Clinical outcomes of oral metronomic vinorelbine in advanced non-small cell lung cancer: correlations with pharmacokinetics and MDR1 polymorphisms. Cancer Chemother Pharmacol. 2019;83(3):493\u2013500.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1492_CR167","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jjco\/hyh029","volume":"34","author":"K Yoh","year":"2004","unstructured":"Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y. High body mass index correlates with increased risk of venous irritation by vinorelbine infusion. Jpn J Clin Oncol. 2004;34(4):206\u20139.","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"1492_CR168","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3727\/096504019X15755437099308","volume":"28","author":"S Nobili","year":"2020","unstructured":"Nobili S, Lavacchi D, Perrone G, Vicini G, Tassi R, Landini I, et al. Vinorelbine in non-small cell lung cancer: real-world data from a single-institution experience. Oncol Res. 2020;28(3):237\u201348.","journal-title":"Oncol Res"},{"issue":"9","key":"1492_CR169","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1007\/s10147-020-01707-9","volume":"25","author":"K Xu","year":"2020","unstructured":"Xu K, Liu T, Zhang J, Zhou Y, Yang F, Ren T. The efficacy and toxicity of metronomic oral vinorelbine monotherapy in patients with non-small cell lung cancer: a meta-analysis. Int J Clin Oncol. 2020;25(9):1624\u201334.","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"1492_CR170","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1200\/JCO.1997.15.4.1395","volume":"15","author":"RB Livingston","year":"1997","unstructured":"Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, et al. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1997;15(4):1395\u2013400.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1492_CR171","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3816\/CBC.2003.n.004","volume":"3","author":"C Jara-S\u00e1nchez","year":"2003","unstructured":"Jara-S\u00e1nchez C, Mart\u00edn M, Garc\u00eda-S\u00e1enz JA, Barnada A, Fern\u00e1ndez-Aramburo A, L\u00f3pez-Vega JM, et al. Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group. Clin Breast Cancer. 2003;3(6):399\u2013404.","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"1492_CR172","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/bcp.14372","volume":"87","author":"BD Menz","year":"2021","unstructured":"Menz BD, Stocker SL, Verougstraete N, Kocic D, Galettis P, Stove CP, Reuter SE. Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology. Br J Clin Pharmacol. 2021;87(2):227\u201336.","journal-title":"Br J Clin Pharmacol"},{"key":"1492_CR173","doi-asserted-by":"crossref","unstructured":"Kim HY, Martin JH, Mclachlan AJ, Boddy AV. Precision dosing of targeted anticancer drugs\u2014challenges in the real world. Transl Cancer Res. 2017:S1500\u2013S11.","DOI":"10.21037\/tcr.2017.10.30"},{"key":"1492_CR174","unstructured":"FDA. Food and Drug Administration\u2014Project Renewal. 2024. https:\/\/www.fda.gov\/about-fda\/oncology-center-excellence\/project-renewal. Accessed 03 Feb 2025."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01492-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01492-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01492-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T15:11:41Z","timestamp":1745939501000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01492-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":174,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1492"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01492-6","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"9 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"M.P. Kicken contributed to conceptualisation, formal analysis, investigation, methodology, project administration, supervision, validation, visualization, writing\u2014original draft and writing\u2014review & editing. R. ter Heine, and M.J. Deenen contributed to conceptualization, formal analysis, investigation, methodology, supervision, validation, writing\u2014original draft and writing\u2014review & editing. B.E.E.M. van den Borne, A.J. van der Wekken, and M.M. van den Heuvel contributed to investigation, writing\u2014review & editing.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}